Início › Câncer Endometrial › Illinois › Chicago
Ensaios clínicos de Câncer Endometrial em Chicago, IL
25 estudos para Câncer Endometrial estão buscando participantes em locais em Chicago e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecrutandoFase 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- e mais 3
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RecrutandoFase 1
- University of Chicago Comprehensive Cancer Center, Chicago
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecrutandoFase 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecrutandoFase 2
- University of Illinois Cancer Center, Chicago
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RecrutandoEstudo observacional
- University of Chicago, Chicago
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecrutandoFase 1
- Research Site, Chicago
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RecrutandoFase 1/2
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecrutandoFase 2
- Northwestern University, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecrutandoFase 1
- Northwestern University Feinberg School of Medicine, Chicago
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecrutandoFase 3
- University of Chicago Medical Center ( Site 5002), Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecrutandoFase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RecrutandoFase 1
- University of Chicago Medical Center, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecrutandoFase 1/2
- Lurie Children's Hospital-Chicago, Chicago
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RecrutandoFase 2
- Northwestern Medicine, Chicago
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecrutandoFase 1/2
- University of Chicago Medical Center, Chicago
A Study of PHST001 in Advanced Solid Tumors
RecrutandoFase 1
- University of Chicago Medical Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecrutandoFase 3
- Research Site, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecrutandoFase 1/2
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
RecrutandoFase 1
- The University of Chicago Medical Center (UCMC), Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RecrutandoFase 1/2
- Northwestern Memorial Hospital, Chicago
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Recrutando
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecrutandoFase 1/2
- University of Chicago Medical Center, Chicago
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Recrutando
- Northwestern Memorial Hospital, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Ensaios de Câncer Endometrial em outras cidades
- Houston, TX68 estudos
- New York City, NY52 estudos
- Boston, MA50 estudos
- Arlington, VA39 estudos
- Nashville, TN38 estudos
- Los Angeles, CA34 estudos
- St. Louis, MO29 estudos
- Philadelphia, PA28 estudos
- San Antonio, TX27 estudos
- Columbus, OH25 estudos
- Queens, NY25 estudos
- Oklahoma City, OK25 estudos
Outros estudos em Chicago
- Câncer de Pulmão de Não Pequenas Células61 estudos
- Câncer de Mama58 estudos
- Câncer (todos os tipos)51 estudos
- Câncer Metastático45 estudos
- Câncer de Próstata45 estudos
- Obesidade41 estudos
- Câncer de Pulmão41 estudos
- Câncer de Ovário36 estudos
- Acidente Vascular Cerebral34 estudos
- Câncer Colorretal33 estudos
- Insuficiência Cardíaca31 estudos
- Sobrepeso28 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.